


PHARMACEUTICAL 2023

Immuneering Corp Rank 91 of 446









PHARMACEUTICAL 2023





The relative strengths and weaknesses of Immuneering Corp are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Immuneering Corp compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 73% points. The greatest weakness of Immuneering Corp is the variable Other Revenues, reducing the Economic Capital Ratio by 17% points.

The company's Economic Capital Ratio, given in the ranking table, is 205%, being 162% points above the market average of 43%.

| Input Variable | Value in 1000 USD |
|---|----------------------|
| Assets, Current | 108,747 |
| Cost of Goods Sold | 158 |
| Intangible Assets | 7,099 |
| Liabilities, Current | 8,054 |
| Liabilities, Non-Current | 4,463 |
| Other Assets | 5,151 |
| Other Compr. Net Income | 19 |
| Other Expenses | 30 |
| Other Liabilities | 0 |
| Other Net Income | 1,231 |
| Other Revenues | 317 |
| Property and Equipment | 1,370 |
| Research and Development | 36,267 |
| Selling, General and Administrative Expense | 15,607 |

| Output Variable | Value in 1000 USD |
|--------------------------|----------------------|
| Assets | 122,367 |
| Liabilities | 12,517 |
| Expenses | 52,062 |
| Revenues | 317 |
| Stockholders Equity | 109,850 |
| Net Income | -50,514 |
| Comprehensive Net Income | -50,504 |
| Economic Capital Ratio | 205% |

